| Peer-Reviewed

Prolactin as a Marker of Active Disease in Systemic Lupus Erythematosus

Received: 29 April 2021     Accepted: 6 August 2021     Published: 19 November 2021
Views:       Downloads:
Abstract

Objetives. To determine the correlation between prolactin levels and disease activity classified based on the Mexican lupus erythematosus disease systemic activity index (MEX SLEDAI). Methods. In this cross-sectional observational study, serum prolactin, age, sex, treatment, as well as manifestations of active disease were determined. Disease activity was evaluated using the Mexican Systemic Lupus Erythematosus Activity Index (MEX-SLEDAI). The correlation of MEX-SLEDAI with prolactin was determined using the Spearman correlation coefficient. The significance of differences between continuous variables was determined with the non-paired Student’s t test and the significance of differences between categorical variables was determined with Chi-square test. Results. 55 patients were included, 10 (18.1%) had MEX-SLEDAI ≥7 and 45 (81.8%) less than 7. A positive correlation was found with a Spearman rho 0.387 (p = 0.004) between the MEX-SLEDAI and the levels serum prolactin. Subjects with active disease and hyperprolactinemia had 80% manifestations at the renal level (p = 0.001). Conclusion. There is significant correlation between prolactin levels and disease activity. Hyperprolactinemia were detected in patients with renal activity as well as those with MEX-SLEDAI ≥7.

Published in International Journal of Biomedical Engineering and Clinical Science (Volume 7, Issue 4)
DOI 10.11648/j.ijbecs.20210704.11
Page(s) 73-76
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Systemic Lupus Erythematosus, MEX-SLEDAI, Prolactin

References
[1] Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. Elsevier Health Sciences; 2018. 1808 p.
[2] McMurray RW, May W. Sex hormones and systemic lupus erythematosus: Review and meta-analysis. Arthritis Rheum. 2003; 48 (8): 2100–10.
[3] Cárdenas-Mondragón G, Ulloa-Aguirre A, Isordia-Salas I, Goffin V, Leaños-Miranda A. Elevated Serum Bioactive Prolactin Concentrations in Patients with Systemic Lupus Erythematosus Are Associated with Disease Activity as Disclosed by Homologous Receptor Bioassays. J Rheumatol. 2007; 34 (7): 1514–21.
[4] Borba VV, Zandman-Goddard G, Shoenfeld Y. Prolactin and autoimmunity. Front Immunol. 2018; 9 (FEB): 1–8.
[5] Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus. 2001; 10 (8): 554–61.
[6] Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol. 1992; 19 (10): 1551–8.
[7] Jara LJ, Vera-Lastra O, Miranda JM, Alcala M, Alvarez-Nemegyei J. Prolactin in human systemic lupus erythematosus. Lupus. 2001; 10 (10): 748–56.
[8] Vera-Lastra O, Mendez C, Jara LJ, Cisneros M, Medina G, Ariza R, et al. Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment. J Rheumatol. 2003; 30 (10): 2140–6.
[9] Jara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vasey FB, Espinoza LR. Hyperprolactinemia in systemic lupus erythematosus: Association with disease activity. Am J Med Sci. 1992; 303 (4): 222–6.
[10] Asyraf, WA Wan, et al. "The association between serum prolactin levels and interleukin-6 and systemic lupus erythematosus activity." Reumatismo 70. 4 (2018): 241-250.
[11] Walker SE, Yu-Lee LY. Overview: Prolactin and autoimmunity. Lupus. 2001; 10 (10): 659.
[12] Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Torres-Aguilar H, Navarro C, et al. Prolactin has a pathogenic role in systemic lupus erythematosus. Immunol Res. 2017; 65 (2): 512–23.
[13] Pacilio M, Migliaresi S, Meli R, Ambrosone L, Bigliardo B, Di Carlo R. Elevated bioactive prolactin levels in systemic lupus erythematosus - Association with disease activity. J Rheumatol. 2001; 28 (10): 2216–21.
Cite This Article
  • APA Style

    Jorge Medina Castillo, María Azucena Ramos Sánchez, Ariana Maia Becerra Márquez. (2021). Prolactin as a Marker of Active Disease in Systemic Lupus Erythematosus. International Journal of Biomedical Engineering and Clinical Science, 7(4), 73-76. https://doi.org/10.11648/j.ijbecs.20210704.11

    Copy | Download

    ACS Style

    Jorge Medina Castillo; María Azucena Ramos Sánchez; Ariana Maia Becerra Márquez. Prolactin as a Marker of Active Disease in Systemic Lupus Erythematosus. Int. J. Biomed. Eng. Clin. Sci. 2021, 7(4), 73-76. doi: 10.11648/j.ijbecs.20210704.11

    Copy | Download

    AMA Style

    Jorge Medina Castillo, María Azucena Ramos Sánchez, Ariana Maia Becerra Márquez. Prolactin as a Marker of Active Disease in Systemic Lupus Erythematosus. Int J Biomed Eng Clin Sci. 2021;7(4):73-76. doi: 10.11648/j.ijbecs.20210704.11

    Copy | Download

  • @article{10.11648/j.ijbecs.20210704.11,
      author = {Jorge Medina Castillo and María Azucena Ramos Sánchez and Ariana Maia Becerra Márquez},
      title = {Prolactin as a Marker of Active Disease in Systemic Lupus Erythematosus},
      journal = {International Journal of Biomedical Engineering and Clinical Science},
      volume = {7},
      number = {4},
      pages = {73-76},
      doi = {10.11648/j.ijbecs.20210704.11},
      url = {https://doi.org/10.11648/j.ijbecs.20210704.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijbecs.20210704.11},
      abstract = {Objetives. To determine the correlation between prolactin levels and disease activity classified based on the Mexican lupus erythematosus disease systemic activity index (MEX SLEDAI). Methods. In this cross-sectional observational study, serum prolactin, age, sex, treatment, as well as manifestations of active disease were determined. Disease activity was evaluated using the Mexican Systemic Lupus Erythematosus Activity Index (MEX-SLEDAI). The correlation of MEX-SLEDAI with prolactin was determined using the Spearman correlation coefficient. The significance of differences between continuous variables was determined with the non-paired Student’s t test and the significance of differences between categorical variables was determined with Chi-square test. Results. 55 patients were included, 10 (18.1%) had MEX-SLEDAI ≥7 and 45 (81.8%) less than 7. A positive correlation was found with a Spearman rho 0.387 (p = 0.004) between the MEX-SLEDAI and the levels serum prolactin. Subjects with active disease and hyperprolactinemia had 80% manifestations at the renal level (p = 0.001). Conclusion. There is significant correlation between prolactin levels and disease activity. Hyperprolactinemia were detected in patients with renal activity as well as those with MEX-SLEDAI ≥7.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Prolactin as a Marker of Active Disease in Systemic Lupus Erythematosus
    AU  - Jorge Medina Castillo
    AU  - María Azucena Ramos Sánchez
    AU  - Ariana Maia Becerra Márquez
    Y1  - 2021/11/19
    PY  - 2021
    N1  - https://doi.org/10.11648/j.ijbecs.20210704.11
    DO  - 10.11648/j.ijbecs.20210704.11
    T2  - International Journal of Biomedical Engineering and Clinical Science
    JF  - International Journal of Biomedical Engineering and Clinical Science
    JO  - International Journal of Biomedical Engineering and Clinical Science
    SP  - 73
    EP  - 76
    PB  - Science Publishing Group
    SN  - 2472-1301
    UR  - https://doi.org/10.11648/j.ijbecs.20210704.11
    AB  - Objetives. To determine the correlation between prolactin levels and disease activity classified based on the Mexican lupus erythematosus disease systemic activity index (MEX SLEDAI). Methods. In this cross-sectional observational study, serum prolactin, age, sex, treatment, as well as manifestations of active disease were determined. Disease activity was evaluated using the Mexican Systemic Lupus Erythematosus Activity Index (MEX-SLEDAI). The correlation of MEX-SLEDAI with prolactin was determined using the Spearman correlation coefficient. The significance of differences between continuous variables was determined with the non-paired Student’s t test and the significance of differences between categorical variables was determined with Chi-square test. Results. 55 patients were included, 10 (18.1%) had MEX-SLEDAI ≥7 and 45 (81.8%) less than 7. A positive correlation was found with a Spearman rho 0.387 (p = 0.004) between the MEX-SLEDAI and the levels serum prolactin. Subjects with active disease and hyperprolactinemia had 80% manifestations at the renal level (p = 0.001). Conclusion. There is significant correlation between prolactin levels and disease activity. Hyperprolactinemia were detected in patients with renal activity as well as those with MEX-SLEDAI ≥7.
    VL  - 7
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • Servicio de Medicina Interna, Hospital de Especialidades No. 25, Instituto Mexicano del Seguro Social, Monterrey, Mexico

  • Servicio de Reumatología, Hospital de Especialidades No. 25, Instituto Mexicano del Seguro Social, Monterrey, Mexico

  • Servicio de Reumatología, Hospital de Especialidades No. 25, Instituto Mexicano del Seguro Social, Monterrey, Mexico

  • Sections